Essential Pharma Acquires Reminyl Oral Capsules from Janssen Pharmaceutica
April 18, 2024
Essential Pharma has acquired rights to Reminyl (galantamine hydrobromide) oral capsules from Janssen Pharmaceutica NV (a Johnson & Johnson company). The deal transfers rights in the EEA, South Korea, Thailand and other current markets (excluding the UK & Ireland, Japan and Latin America), expanding Essential Pharma’s CNS portfolio and its presence in the Asia‑Pacific region.
- Buyers
- Essential Pharma
- Targets
- Reminyl (galantamine hydrobromide) oral capsules
- Sellers
- Janssen Pharmaceutica NV, Johnson & Johnson
- Industry
- Pharmaceuticals
- Location
- Antwerp, Belgium
- Transaction Type
- Divestiture
Explore More
Related Acquisitions
-
Essential Pharma Acquires HALDOL Rights from Janssen Pharmaceutica NV
December 7, 2022
Pharmaceuticals
Gyrus Capital-backed Essential Pharma has acquired global rights to HALDOL (haloperidol) and HALDOL Decanoate from Janssen Pharmaceutica NV. The deal expands Essential Pharma's specialty CNS portfolio and secures continued global supply of this WHO-listed essential antipsychotic marketed in the US and more than 60 countries.
-
Pharmanovia Acquires Global CNS Portfolio from Sanofi
September 18, 2023
Pharmaceuticals
Pharmanovia, a Triton Fund V portfolio company, has acquired an 11‑brand global central nervous system (CNS) portfolio from Sanofi, including Frisium (clobazam) and Gardenal (phenobarbital). The asset package, available in 60+ markets, expands Pharmanovia's neurology franchise and commercial footprint across markets such as Brazil, South Africa, France and Italy in a divestiture from Sanofi.
-
Essential Pharma Acquires Yorkdale Pharma from Rosemont; Sells Oral Liquid Portfolio to Rosemont and Buys Two Product Rights from Novartis
December 21, 2021
Pharmaceuticals
Gyrus Capital‑backed Essential Pharma completed a refinancing and executed a series of portfolio transactions in December 2021. Essential Pharma acquired Yorkdale Pharma Limited from Rosemont Pharmaceuticals, divested its 14‑product oral liquid portfolio (Essential Pharma Liquids Limited) to Rosemont, and also acquired worldwide (ex‑US, ex‑India) rights to two products from Novartis to expand its global specialty pharmaceutical portfolio.
-
Essential Pharma Acquires Renaissance Pharma Ltd
April 2, 2024
Pharmaceuticals
Essential Pharma has completed the acquisition of all issued share capital of Renaissance Pharma Ltd, gaining the clinical-stage immunotherapy Hu14.18K322A (Hu14.18) for treatment of high‑risk neuroblastoma. The deal adds a development‑stage rare disease oncology asset to Essential Pharma's portfolio; Renaissance's CEO Simon Ball and members of the Renaissance team will continue to work with Essential on further development in partnership with St. Jude Children's Research Hospital.
-
Johnson & Johnson Acquires Intra-Cellular Therapies
April 2, 2025
Pharmaceuticals
Johnson & Johnson has completed its acquisition of Intra-Cellular Therapies, adding the approved drug CAPLYTA (lumateperone) and a clinical-stage neuroscience pipeline to J&J's Innovative Medicine business. The deal is expected to accelerate J&J's 2025 sales growth and strengthen its leadership in neuroscience and mental health therapeutics.
-
Nutra-Med Acquires Legacy Pharma Solutions
October 22, 2024
Manufacturing
Nutra-Med, a portfolio company of GenNx360 Capital Partners, has acquired Legacy Pharma Solutions, a St. Louis-based provider of oral solid dose contract packaging. The acquisition adds high-speed bottling and blistering capabilities to Nutra-Med, expanding its contract packaging capacity for pharmaceutical, OTC and medical device customers.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.